Latest news with #RepareTherapeutics
National Post
13-05-2025
- Business
- National Post
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results
Article content Article content $124.2 million in cash and cash equivalents and marketable securities provides runway as of March 31, 2025 Article content CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. ('Repare' or the 'Company') (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2025. Article content 'During the first quarter of 2025 we continued our efforts to create long-term value for our shareholders via partnering and by advancing our novel pipeline programs,' said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. 'We announced a strategic partnership with DCx Biotherapeutics to out-license our discovery platforms, and we are exploring a full range of strategic alternatives and partnerships across our portfolio. We are well-positioned from an operational and financial standpoint to drive our clinical pipeline to key inflection points and remain on track to report initial data for both the LIONS and POLAR trials in the second half of this year.' Article content First Quarter 2025 and Recent Portfolio Highlights: Article content Announced out-licensing of its discovery platforms to DCx Biotherapeutics Repare announced it out-licensed its early-stage discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation ('DCx'). In connection with this agreement, Repare will receive upfront and near-term payments totaling $4 million, as well as a 9.99% equity position in DCx, including certain dilution protection rights, and is eligible to receive potential future out-licensing, clinical and commercial milestone payments, as well as low single-digit sales royalties for the development of certain products by DCx. Additionally, DCx will retain approximately 20 of Repare's preclinical research employees. Article content RP-3467: Potential best-in-class, oral Polθ ATPase/helicase inhibitor Repare is conducting a Phase 1 clinical trial of RP-3467 (POLAR), dosing patients alone and in combination with the poly-ADP ribose polymerase (PARP) inhibitor, olaparib. POLAR is a multicenter, open-label, dose-escalation Phase 1 clinical trial designed to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3647 alone or in combination with olaparib in adults with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer, or pancreatic adenocarcinoma. Upcoming expected milestone: Q3 2025: Topline safety, tolerability and early efficacy data from the POLAR trial in monotherapy and in combination with olaparib. Article content RP-1664: First-in-class, oral selective PLK4 Inhibitor Repare completed enrolment of 29 patients in its Phase 1 LIONS clinical trial, evaluating RP-1664 as a monotherapy in adult and adolescent patients with TRIM37-high solid tumors. LIONS is a first-in-human, multicenter, open-label Phase 1 clinical trial designed to investigate safety, pharmacokinetics, pharmacodynamics and the preliminary efficacy of RP-1664. Upcoming expected milestone: Article content Lunresertib (RP-6306) Repare is currently evaluating lunresertib in combination with Debio 0123, a highly selective, brain-penetrant, clinical WEE1 inhibitor, in patients with advanced solid tumors harboring CCNE1 amplification or FBXW7 or PPP2R1A deleterious alterations as part of an ongoing 50/50 cost sharing collaboration with Debiopharm. Repare does not intend to continue to develop lunresertib in any other trials, absent securing a partnership with a development partner. Article content Cash, cash equivalents and marketable securities: Cash, cash equivalents and marketable securities as of March 31, 2025 were $124.2 million, as compared to $152.8 million as of December 31, 2024. The Company believes that its cash, cash equivalents, and marketable securities are sufficient to fund its current operational plans through 2027. Revenue from collaboration agreements: Revenue from collaboration agreements was nil and $52.4 million for the three months ended March 31, 2025 and 2024, respectively. Research and development expense, net of tax credits (Net R&D): Net R&D expenses were $20.3 million and $33.0 million for the three months ended March 31, 2025 and 2024, respectively. General and administrative (G&D) expenses: G&A expenses were $7.7 million and $8.6 million for the three months ended March 31, 2025 and 2024, respectively. Net income (loss): Net loss was $30.1 million, or $0.71 per diluted share, and $13.2 million, or $0.30 per diluted share, for the three months ended March 31, 2025 and 2024, respectively. Article content About Repare Therapeutics Inc. Article content Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor; and lunresertib, a PKMYT1 inhibitor. For more information, please visit and follow @Reparerx on X (formerly Twitter) and LinkedIn. Article content This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are 'forward-looking statements. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company's out-license of its discovery platforms to DCx, including the potential benefits of the transaction and the receipt of out-licensing, clinical and commercial milestone payments and royalties under the out-license agreement; the Company's plans for exploring strategic alternatives and partnerships across the clinical portfolio, including the Company's plans to seek a partner to fund further clinical development of lunresertib and other assets; the Company's anticipated cash runway; the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of the Company's product candidates including the advancement of its three ongoing clinical trials. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company's ability to successfully pursue a strategic transaction on attractive terms, or at all; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including tariffs and other trade policies, the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and uncertain credit and financial markets, on the Company's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company's ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') and the Québec Autorité des Marchés Financiers ('AMF') on March 3, 2025., and in other filings made with the SEC and AMF from time to time, including the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at Article content Article content Article content Article content Contacts Article content Article content Article content
Ottawa Citizen
25-04-2025
- Business
- Ottawa Citizen
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
Article content CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. ('Repare' or the 'Company') (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Article content Article content Mini-Oral Presentation Details: Title: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656) Presenter: Alison M. Schram, MD, Memorial Sloan Kettering Cancer Center Session: Innovative Approaches to Key Molecular Targets Session Date and Time: Tuesday, April 29 from 2:30-4:30 p.m. CT Location: Room S406 (Vista Ballroom) Abstract Number: CT262 Article content Article content Title: The PLK4 inhibitor RP-1664 drives centriole modulation and single agent tumor regressions in preclinical neuroblastoma models Presenter: John M. Maris, MD, Children's Hospital of Philadelphia Session: Advancing the Science of Childhood Cancers: From Bench to Bedside Session Date and Time: Sunday, April 27 from 3:00-5:00 p.m. CT Location: Room E353 C Abstract Number: 1201 Article content Poster Presentation Details: Article content Title: A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma Presenter: Michal Zimmermann, PhD, Repare Therapeutics Session: Cell Cycle Effects of Anticancer Drugs Session Date and Time: Sunday, April 27 from 2:00-5:00 p.m. CT Location: Poster Section 17 Poster Number: 9 Abstract Number: 365 Article content Title: RP-1664: A potent and selective PLK4 inhibitor causing tumor regressions in TRIM37-high xenograft models of solid tumors Presenter: Anne Roulston, PhD, Repare Therapeutics Session: Kinase and Phosphatase Inhibitors 1 Session Date and Time: Monday, April 28 from 9:00 a.m-12:00 p.m. CT Location: Poster Section 21 Poster Number: 9 Abstract Number: 1734 Article content Title: Pan-cancer analysis of TRIM37 copy-number and development of fit-for-screening in situ hybridization tools Presenter: Isabel Soria-Bretones, PhD, Repare Therapeutics Session: Diagnostic Biomarkers 2 Session Date and Time: Sunday, April 27 from 2:00-5:00 p.m. CT Location: Poster Section 31 Poster Number: 2 Abstract Number: 717 Article content Title: Targeting CCNE1 amplification in gastric cancer Presenter: Sung Joo Jang, Columbia University Irving Medical Center Session: Protein Kinases and Phosphatases as Targets for Therapy Session Date and Time: Wednesday, April 30 from 9:00 a.m.-12:00 p.m. CT Location: Poster Section 24 Poster Number: 4 Abstract Number: 6942 Article content A copy of each poster presentation is available on the Scientific Resources page of the Repare Therapeutics website and a copy of each mini-oral presentation will be available on the Scientific Resources page of the Repare Therapeutics website at the start of each mini-oral session. Article content Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx ® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a Phase 1 Polθ ATPase inhibitor; and lunresertib, a PKMYT1 inhibitor. For more information, please visit and follow @Reparerx on X (formerly Twitter) and LinkedIn. Article content Article content Article content Article content Article content
National Post
25-04-2025
- Health
- National Post
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
Article content CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. ('Repare' or the 'Company') (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Article content Article content Mini-Oral Presentation Details: Title: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656) Presenter: Alison M. Schram, MD, Memorial Sloan Kettering Cancer Center Session: Innovative Approaches to Key Molecular Targets Session Date and Time: Tuesday, April 29 from 2:30-4:30 p.m. CT Location: Room S406 (Vista Ballroom) Abstract Number: CT262 Article content Title: The PLK4 inhibitor RP-1664 drives centriole modulation and single agent tumor regressions in preclinical neuroblastoma models Presenter: John M. Maris, MD, Children's Hospital of Philadelphia Session: Advancing the Science of Childhood Cancers: From Bench to Bedside Session Date and Time: Sunday, April 27 from 3:00-5:00 p.m. CT Location: Room E353 C Abstract Number: 1201 Article content Poster Presentation Details: Article content Title: A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma Presenter: Michal Zimmermann, PhD, Repare Therapeutics Session: Cell Cycle Effects of Anticancer Drugs Session Date and Time: Sunday, April 27 from 2:00-5:00 p.m. CT Location: Poster Section 17 Poster Number: 9 Abstract Number: 365 Article content Title: RP-1664: A potent and selective PLK4 inhibitor causing tumor regressions in TRIM37-high xenograft models of solid tumors Presenter: Anne Roulston, PhD, Repare Therapeutics Session: Kinase and Phosphatase Inhibitors 1 Session Date and Time: Monday, April 28 from 9:00 a.m-12:00 p.m. CT Location: Poster Section 21 Poster Number: 9 Abstract Number: 1734 Article content Title: Pan-cancer analysis of TRIM37 copy-number and development of fit-for-screening in situ hybridization tools Presenter: Isabel Soria-Bretones, PhD, Repare Therapeutics Session: Diagnostic Biomarkers 2 Session Date and Time: Sunday, April 27 from 2:00-5:00 p.m. CT Location: Poster Section 31 Poster Number: 2 Abstract Number: 717 Article content Title: Targeting CCNE1 amplification in gastric cancer Presenter: Sung Joo Jang, Columbia University Irving Medical Center Session: Protein Kinases and Phosphatases as Targets for Therapy Session Date and Time: Wednesday, April 30 from 9:00 a.m.-12:00 p.m. CT Location: Poster Section 24 Poster Number: 4 Abstract Number: 6942 Article content A copy of each poster presentation is available on the Scientific Resources page of the Repare Therapeutics website and a copy of each mini-oral presentation will be available on the Scientific Resources page of the Repare Therapeutics website at the start of each mini-oral session. Article content Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx ® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a Phase 1 Polθ ATPase inhibitor; and lunresertib, a PKMYT1 inhibitor. For more information, please visit and follow @Reparerx on X (formerly Twitter) and LinkedIn. Article content Article content Article content Article content Article content
Business Wire
25-04-2025
- Business
- Business Wire
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. ('Repare' or the 'Company') (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Mini-Oral Presentation Details: Title: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656) Presenter: Alison M. Schram, MD, Memorial Sloan Kettering Cancer Center Session: Innovative Approaches to Key Molecular Targets Session Date and Time: Tuesday, April 29 from 2:30-4:30 p.m. CT Location: Room S406 (Vista Ballroom) Abstract Number: CT262 Title: The PLK4 inhibitor RP-1664 drives centriole modulation and single agent tumor regressions in preclinical neuroblastoma models Presenter: John M. Maris, MD, Children's Hospital of Philadelphia Session: Advancing the Science of Childhood Cancers: From Bench to Bedside Session Date and Time: Sunday, April 27 from 3:00-5:00 p.m. CT Location: Room E353 C Abstract Number: 1201 Poster Presentation Details: Title: A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma Presenter: Michal Zimmermann, PhD, Repare Therapeutics Session: Cell Cycle Effects of Anticancer Drugs Session Date and Time: Sunday, April 27 from 2:00-5:00 p.m. CT Location: Poster Section 17 Poster Number: 9 Abstract Number: 365 Title: RP-1664: A potent and selective PLK4 inhibitor causing tumor regressions in TRIM37-high xenograft models of solid tumors Presenter: Anne Roulston, PhD, Repare Therapeutics Session: Kinase and Phosphatase Inhibitors 1 Session Date and Time: Monday, April 28 from 9:00 a.m-12:00 p.m. CT Location: Poster Section 21 Poster Number: 9 Abstract Number: 1734 Title: Pan-cancer analysis of TRIM37 copy-number and development of fit-for-screening in situ hybridization tools Presenter: Isabel Soria-Bretones, PhD, Repare Therapeutics Session: Diagnostic Biomarkers 2 Session Date and Time: Sunday, April 27 from 2:00-5:00 p.m. CT Location: Poster Section 31 Poster Number: 2 Abstract Number: 717 Title: Targeting CCNE1 amplification in gastric cancer Presenter: Sung Joo Jang, Columbia University Irving Medical Center Session: Protein Kinases and Phosphatases as Targets for Therapy Session Date and Time: Wednesday, April 30 from 9:00 a.m.-12:00 p.m. CT Location: Poster Section 24 Poster Number: 4 Abstract Number: 6942 A copy of each poster presentation is available on the Scientific Resources page of the Repare Therapeutics website and a copy of each mini-oral presentation will be available on the Scientific Resources page of the Repare Therapeutics website at the start of each mini-oral session. About Repare Therapeutics Inc. Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx ® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a Phase 1 Polθ ATPase inhibitor; and lunresertib, a PKMYT1 inhibitor. For more information, please visit and follow @Reparerx on X (formerly Twitter) and LinkedIn.
Yahoo
04-03-2025
- Business
- Yahoo
Here's Why We're Watching Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while history lauds those rare successes, those that fail are often forgotten; who remembers So should Repare Therapeutics (NASDAQ:RPTX) shareholders be worried about its cash burn? For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway. See our latest analysis for Repare Therapeutics A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. In December 2024, Repare Therapeutics had US$153m in cash, and was debt-free. Importantly, its cash burn was US$76m over the trailing twelve months. Therefore, from December 2024 it had 2.0 years of cash runway. While that cash runway isn't too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. Depicted below, you can see how its cash holdings have changed over time. We reckon the fact that Repare Therapeutics managed to shrink its cash burn by 41% over the last year is rather encouraging. And operating revenue was up by 4.6% too. Considering the factors above, the company doesn't fare badly when it comes to assessing how it is changing over time. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company. While Repare Therapeutics seems to be in a fairly good position, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations. Since it has a market capitalisation of US$50m, Repare Therapeutics' US$76m in cash burn equates to about 152% of its market value. Given just how high that expenditure is, relative to the company's market value, we think there's an elevated risk of funding distress, and we would be very nervous about holding the stock. Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought Repare Therapeutics' cash runway was relatively promising. Summing up, we think the Repare Therapeutics' cash burn is a risk, based on the factors we mentioned in this article. Separately, we looked at different risks affecting the company and spotted 4 warning signs for Repare Therapeutics (of which 2 are significant!) you should know about. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts) Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
